Advertisement
Screener

COMPASS THERAPEUTICS, INC. (CMPX) Financing Cash Flow

2.8 / 5 stars · 68/120 Roast Me

COMPASS THERAPEUTICS, INC. Financing Cash Flow

COMPASS THERAPEUTICS, INC. (CMPX) reported Financing Cash Flow of $3.37 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Cash Flow › Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06

  • COMPASS THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $0.00.
  • COMPASS THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $3.37M.
  • COMPASS THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $1.06M.
  • COMPASS THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $129.36M.
  • COMPASS THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $129.61M, a 647.54% increase from fiscal 2024.
  • COMPASS THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $17.34M, a 490.73% increase from fiscal 2023.
  • COMPASS THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $2.94M, a 96.13% decline from fiscal 2022.
  • COMPASS THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $75.76M, a 36.13% decline from fiscal 2021.
Period endNet Cash Provided by (Used in) Financing Activities 0 monthNet Cash Provided by (Used in) Financing Activities 3 monthNet Cash Provided by (Used in) Financing Activities 6 monthNet Cash Provided by (Used in) Financing Activities 9 monthNet Cash Provided by (Used in) Financing Activities 12 month
2026-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
$3.37M
10-Q · filed 2026-08-06
$4.43M
derived: sum of 3 quarters · filed 2026-08-06
$133.79M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$3.37M
10-Q · filed 2026-05-05
$4.43M
derived: sum of 2 quarters · filed 2026-05-05
$133.79M
derived: sum of 3 quarters · filed 2026-05-05
$133.79M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31$1.06M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05
$130.42M
derived: sum of 2 quarters · filed 2026-03-05
$130.42M
derived: sum of 3 quarters · filed 2026-08-06
$129.61M
10-K · filed 2026-03-05
2025-09-30$129.36M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
$129.36M
derived: sum of 2 quarters · filed 2026-08-06
$128.55M
10-Q · filed 2025-11-05
$128.45M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$815.00K
10-Q · filed 2026-08-06
-$909.00K
derived: sum of 3 quarters · filed 2026-08-06
-$911.00K
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31-$815.00K
10-Q · filed 2026-05-05
-$909.00K
derived: sum of 2 quarters · filed 2026-05-05
-$911.00K
derived: sum of 3 quarters · filed 2026-05-05
-$910.00K
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31-$94.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05
-$96.00K
derived: sum of 2 quarters · filed 2026-03-05
-$95.00K
derived: sum of 3 quarters · filed 2026-03-05
$17.34M
10-K · filed 2026-03-05
2024-09-30-$2.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
-$1.00K
derived: sum of 2 quarters · filed 2025-11-05
$17.43M
10-Q · filed 2025-11-05
$17.27M
derived: sum of 4 quarters · filed 2025-11-05
2024-06-30$1.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11
$17.43M
10-Q · filed 2025-08-11
$17.28M
derived: sum of 3 quarters · filed 2025-08-11
$17.30M
derived: sum of 4 quarters · filed 2025-08-11
2024-03-31$17.43M
10-Q · filed 2025-05-08
$17.27M
derived: sum of 2 quarters · filed 2025-05-08
$17.30M
derived: sum of 3 quarters · filed 2025-05-08
$20.33M
derived: sum of 4 quarters · filed 2025-05-08
2023-12-31-$158.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27
-$137.00K
derived: sum of 2 quarters · filed 2025-02-27
$2.89M
derived: sum of 3 quarters · filed 2025-02-27
$2.94M
10-K · filed 2025-02-27
2023-09-30$21.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
$3.05M
derived: sum of 2 quarters · filed 2024-11-12
$3.09M
10-Q · filed 2024-11-12
$78.84M
derived: sum of 4 quarters · filed 2024-11-12
2023-06-30$3.03M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12
$3.07M
10-Q · filed 2024-08-12
$78.82M
derived: sum of 3 quarters · filed 2024-08-12
$78.83M
derived: sum of 4 quarters · filed 2024-08-12
2023-03-31$41.00K
10-Q · filed 2024-05-13
$75.79M
derived: sum of 2 quarters · filed 2024-05-13
$75.80M
derived: sum of 3 quarters · filed 2024-05-13
$75.80M
derived: sum of 4 quarters · filed 2024-05-13
2022-12-31$75.75M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21
$75.76M
derived: sum of 2 quarters · filed 2024-03-21
$75.76M
derived: sum of 3 quarters · filed 2024-03-21
$75.76M
10-K · filed 2024-03-21
2022-09-30$5.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
$5.00K
derived: sum of 2 quarters · filed 2023-11-09
$5.00K
10-Q · filed 2023-11-09
$124.24M
derived: sum of 4 quarters · filed 2023-11-09
2022-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03
$0.00
10-Q · filed 2023-08-03
$124.24M
derived: sum of 3 quarters · filed 2023-08-03
$122.36M
derived: sum of 4 quarters · filed 2023-08-03
2022-03-31$0.00
10-Q · filed 2023-05-04
$124.24M
derived: sum of 2 quarters · filed 2023-05-04
$122.36M
derived: sum of 3 quarters · filed 2023-05-04
$120.49M
derived: sum of 4 quarters · filed 2023-05-04
2021-12-31$124.24M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15
$122.36M
derived: sum of 2 quarters · filed 2023-03-15
$120.49M
derived: sum of 3 quarters · filed 2023-03-15
$118.61M
10-K · filed 2023-03-15
2021-09-30-$1.88M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09
-$3.75M
derived: sum of 2 quarters · filed 2022-11-09
-$5.63M
10-Q · filed 2022-11-09
2021-06-30-$1.88M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16
-$3.75M
10-Q · filed 2021-08-16
2021-06-20-$1.88M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-01
-$3.75M
10-Q · filed 2022-08-01
-$5.63M
derived: sum of 3 quarters · filed 2022-08-01
-$8.30M
derived: sum of 4 quarters · filed 2022-08-01
2021-03-31-$1.88M
10-Q · filed 2022-05-09
-$3.75M
derived: sum of 2 quarters · filed 2022-05-09
-$6.43M
derived: sum of 3 quarters · filed 2022-05-09
2020-12-31-$1.88M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18
-$4.55M
derived: sum of 2 quarters · filed 2022-03-18
$48.54M
10-K · filed 2022-03-18
2020-09-30-$2.68M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12
$50.41M
10-Q · filed 2021-11-12
2020-06-30$53.09M
10-Q · filed 2021-08-16
2020-03-31$10.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-08
$17.50K
derived: sum of 2 quarters · filed 2020-06-08
$30.98K
10-K · filed 2020-06-08
2019-12-31$7.50K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-02-14
$20.98K
10-Q · filed 2020-02-14
2019-09-30$13.48K
10-Q · filed 2019-11-13
2019-03-31$10.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-08
$22.50K
derived: sum of 2 quarters · filed 2020-06-08
$22.50K
derived: sum of 3 quarters · filed 2020-06-08
$37.63K
10-K · filed 2020-06-08
2018-12-31$12.50K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-02-14
$12.50K
derived: sum of 2 quarters · filed 2020-02-14
$27.63K
10-Q · filed 2020-02-14
2018-09-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-11-13
$15.13K
10-Q · filed 2019-11-13
2018-06-30$15.13K
10-Q · filed 2019-08-13
2018-03-31$35.00K
10-K · filed 2019-07-01

Similar stocks

Stock NameCountryMarket CapPE Ratio
Protara Therapeutics, Inc. (TARA)United States$0.198B-3.22
Alector, Inc. (ALEC)United States$0.213B-1.90
ANAVEX LIFE SCIENCES CORP. (AVXL)United States$0.218B-18.37
Protalix BioTherapeutics, Inc. (PLX)$0.221B9.87
Alpha Cognition Inc. (ACOG)$0.185B-6.77
Coherus Oncology, Inc. (CHRS)United States$0.182B-1.63
PRECISION BIOSCIENCES INC (DTIL)United States$0.175B-3.95
Voyager Therapeutics, Inc. (VYGR)United States$0.173B-1.99
Aligos Therapeutics, Inc. (ALGS)United States$0.238B-0.47
Lineage Cell Therapeutics, Inc. (LCTX)United States$0.241B-10.35